Report

North America Proteomics Market Analysis

The North America proteomics market size stands at USD 13.26 billion in 2025 and is forecast to reach USD 22.76 billion by 2030, registering an 11.41% CAGR. Rising integration of artificial intelligence with modern mass-spectrometry platforms, steady consolidation among instrument suppliers, and expanding venture capital flows into multi-omics start-ups combined to keep the region ahead of global peers. Strategic deals, such as Thermo Fisher Scientific's USD 3.1 billion purchase of Olink, show how incumbents lock in next-generation protein-analysis assets to shorten discovery timelines. United States-based pharmaceutical sponsors dominate early-stage demand for high-throughput workflows, while smaller biotechnology firms and academic users increasingly rely on contract research organizations to offset capital barriers. Fuel for long-run growth also comes from regulatory moves that give clinical laboratories clearer pathways to adopt proteomic diagnostics, pushing hospitals and reference labs to modernize their analytical fleets.

North America Proteomics Market Trends and Insights



Escalating Adoption of Personalized Medicine

Precision oncology programs now embed deep-visual proteomics to guide therapy selection at the individual tumor-cell level. The FDA cleared four peptide-based therapeutics in 2024, demonstrating regulatory confidence in protein-driven interventions. Healthcare systems increasingly recognize that real-time protein signatures improve treatment prediction accuracy more than genomic markers alone, especially in cancers where expression profiles shift during disease progression. Demand therefore rises for high-sensitivity instruments able to quantify low-abundance proteins directly from clinical samples. These needs sustain premium pricing for novel Orbitrap and acoustic-ejection platforms that cut run times without sacrificing depth. As payers link reimbursement to measurable outcomes, laboratories prioritize assays that translate protein dynamics into actionable decisions, further lifting the North America proteomics market.

Surge in Proteomics-Specific Funding

Venture investors have made large follow-on commitments to companies combining live-cell imaging with AI analytics. Eikon's USD 351 million raise in February 2025 pushed the firm's valuation to USD 3.1 billion and signaled broad confidence in protein-tracking drug-discovery engines. Public support mirrors private enthusiasm: Canada's skills strategy projects 65,000 additional bioeconomy workers by 2029, including 16,140 roles focused on biomanufacturing. With new capital, start-ups generate proprietary interaction datasets at unprecedented scale, erecting entry barriers that established players must address through partnerships or acquisitions. High liquidity, coupled with clear clinical use-cases, sustains the funding wave that underpins expansion of the North America proteomics market.

High Capital Cost of Instruments

Flagship mass-spectrometry units can cost well above USD 1 million, a hurdle that delayed orders in 2024. Bio-Rad Laboratories saw its life-science sales slip 16.5% in Q2 2024 as customers deferred purchases, prompting the firm to guide full-year revenue down 2.5% to 4.0%. Smaller biotechs and academic centers lack balance-sheet flexibility, leading them to rent time at core facilities or engage service labs. Leasing smooths cash flow but raises lifetime operating expense. Rapid innovation also shortens depreciation cycles, forcing caution on buyers and trimming short-term growth for the North America proteomics market.

Other drivers and restraints analyzed in the detailed report include:

Breakthroughs in High-Throughput MS Platforms / Expansion of Biopharma Proteomics Spending / Bioinformatics Talent Shortage /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents captured 63.41% of the North America proteomics market share in 2024 because every experiment requires fresh antibodies, enzymes, buffers, and labeling kits. Suppliers lock in predictable revenue by bundling consumables with instruments. The software & services slice is much smaller, yet it delivers a 12.85% CAGR because laboratories must extract insights from high-volume data. Cloud platforms equipped with pretrained AI models simplify spectrum annotation, protein-protein interaction mapping, and clinical-trial report generation. Instruments command premium prices but represent a cyclical buy-decision. Vendors therefore tie service contracts to hardware to smooth cash flows and improve customer retention across the North America proteomics market.

Growth in software also reflects a pivot toward subscription models. Data analysis portals charge per sample or per month, turning unpredictable capital expenses into operating budgets. Managed-service firms now integrate LIMS, statistical pipelines, and regulatory-grade audit trails, letting understaffed hospitals gain modern capabilities without hiring full-time bioinformaticians. As data volumes swell, so does demand for encrypted cloud storage, backup, and cyber-security audits. Each of these trends adds momentum to the North America proteomics industry and lifts long-run platform value for developers who can enable seamless reagent-to-report workflows.

Mass spectrometry held 28.27% of the North America proteomics market size in 2024, reflecting decades of reliability, vast legacy datasets, and broad regulatory acceptance. High-resolution Orbitrap and time-of-flight systems now pair with foundation AI models that predict spectrum quality and post-translational modifications in real time. Next-generation sequencing platforms chart a 13.02% CAGR because vendors blend genomics, transcriptomics, and proteomics into single multi-omics reads. Illumina plans to commercialize spatial transcriptomics add-ons by 2026, combining its sequencers with NVIDIA GPUs to accelerate protein-structure insight within oncology studies.

Microfluidic sample-handling tools shrink reaction volumes, enabling low-cost point-of-care tests for infectious-disease proteotyping. Chromatography and capillary electrophoresis retain niche relevance for sample cleanup, while protein microarrays support high-throughput antibody discovery. Hybrid instruments that combine MS, NGS, and fluorescence-imaging modules reduce laboratory footprints and maximize asset utilization. Such convergence improves workflow efficiency, keeping end users loyal to suppliers that provide total solutions, thereby expanding the North America proteomics market.

The North America Proteomics Market Report is Segmented by Component (Instruments and More), Technology (Mass Spectrometry and More), Application (Drug Discovery & Development and More), End-User (Pharmaceutical & Biotechnology Companies and More), and Geography (United States, Canada, and Mexico). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

Agilent Technologies / Alamar Biosciences, Inc. / Bioinformatics Solutions Inc. / Bio-Rad Laboratories / Bruker / Creative Proteomics / Danaher / GE�Healthcare / Illumina / Merck / Nautilus Biotechnology / Oxford Nanopore Technologies / Promega / QIAGEN / Revvity, Inc. / Seer / Shimadzu / SomaLogic / Thermo Fisher Scientific / Waters Corporation /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /